Semaglutide for Alcoholism in HIV

(GL1DER HIV RCT Trial)

This trial explores whether semaglutide, a medication typically used for diabetes and weight management, can help reduce alcohol consumption in people living with HIV. The researchers aim to determine if semaglutide also decreases cigarette smoking and lowers heart disease risk in this group. Participants will receive either semaglutide or a placebo to compare effects. This trial suits individuals with HIV who drink alcohol regularly and are currently on HIV medications. Participants must visit the clinic for checkups and tests while taking the medication for three months. As a Phase 2 trial, this research focuses on measuring the treatment's effectiveness in an initial, smaller group of people.

The trial does not specify if you need to stop taking your current medications, but you must not be taking GLP-1 RA medications in the past 3 months. It's best to discuss your specific medications with the trial team.

Research has shown that semaglutide is generally well-tolerated. In earlier studies, participants reported fewer days of heavy drinking and a reduced desire to drink alcohol when taking semaglutide compared to a placebo. This suggests that the drug can work effectively without causing major side effects. Another study found that semaglutide also helped reduce alcohol and cigarette use among participants. These results support the safety of semaglutide, especially since it is already approved for other uses. However, like any medication, it may cause some side effects, so discussing any concerns with a healthcare provider is important.¹²³⁴⁵

Semaglutide is unique because it targets alcoholism in individuals with HIV through a novel mechanism of action. Unlike traditional treatments for alcoholism, which often focus on behavioral therapies and medications like naltrexone or disulfiram, semaglutide is primarily known as a diabetes medication that impacts the GLP-1 receptor. This receptor is involved in regulating appetite and reward pathways, which could help reduce alcohol cravings and consumption. Researchers are excited about semaglutide because it offers a new approach by leveraging its effects on metabolism and cravings, potentially providing a dual benefit for people with HIV who experience alcohol use disorder.

Research has shown that semaglutide can help people reduce alcohol consumption. In some studies, participants taking semaglutide drank fewer alcoholic beverages each week compared to those taking a placebo, a pill with no active medicine. Semaglutide also reduced their cravings for alcohol. This trial will compare semaglutide with a placebo to evaluate its effectiveness in reducing alcohol consumption in individuals with HIV. Additionally, some studies found that semaglutide helped smokers cut down on cigarettes. Researchers are studying this drug for its potential to help people drink and smoke less, which could also lower health risks.¹²³⁴⁵